Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol

[1]  S. Knight,et al.  Alemtuzumab Induction Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis , 2012, Transplantation.

[2]  E. Thervet,et al.  Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four‐Year Results of the Postconcept Study , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  S. Mulgaonkar,et al.  Alemtuzumab induction in renal transplantation. , 2011, The New England journal of medicine.

[4]  J. Chapman.  Chronic Calcineurin Inhibitor Nephrotoxicity—Lest We Forget , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  A. Matas.  Chronic Progressive Calcineurin Nephrotoxicity: An Overstated Concept , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  Thomas Becker,et al.  Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial , 2011, The Lancet.

[7]  E. Thervet,et al.  Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  F. Schena,et al.  Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial , 2009, Transplantation.

[9]  S. Flechner.  Reviewing the evidence for de novo immunosuppression with sirolimus. , 2008, Transplantation proceedings.

[10]  J. Gill,et al.  ALEMTUZUMAB INDUCTION IN LIVING DONOR KIDNEY TRANSPLANTATION: AN ANALYSIS USING THE OPTN/UNOS DATABASE: 875 , 2008 .

[11]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[12]  N. Perico,et al.  Regulatory T cells and T cell depletion: role of immunosuppressive drugs. , 2007, Journal of the American Society of Nephrology : JASN.

[13]  G. Knoll,et al.  Conversion From Calcineurin Inhibitors to Sirolimus for Chronic Renal Allograft Dysfunction: A Systematic Review of the Evidence , 2006, Transplantation.

[14]  Y. Becker,et al.  Outcomes at 3 years of a prospective pilot study of Campath‐1H and sirolimus immunosuppression for renal transplantation , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  M. Unruh,et al.  Living Donor Renal Transplantation Using Alemtuzumab Induction and Tacrolimus Monotherapy , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  R. Marcus,et al.  Anthracycline-based Chemotherapy as First-line Treatment in Adults with Malignant Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation , 2006, Transplantation.

[17]  D. Valmori,et al.  Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.

[18]  G. Remuzzi,et al.  Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[19]  J. Fechner,et al.  T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients , 2006, Transplantation.

[20]  A. Kirk,et al.  Results from a Human Renal Allograft Tolerance Trial Evaluating T-Cell Depletion with Alemtuzumab Combined with Deoxyspergualin , 2005, Transplantation.

[21]  J. Chapman,et al.  Chronic renal allograft dysfunction. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  D. Goldfarb,et al.  The natural history of chronic allograft nephropathy. , 2005, The Journal of urology.

[23]  J. Schold,et al.  Long‐Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies? , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  J. Bradley,et al.  Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. , 2000, Nihon Geka Gakkai zasshi.

[25]  R. Wolfe,et al.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. , 1999, The New England journal of medicine.

[26]  T. Strom,et al.  Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance , 1999, Nature Medicine.

[27]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[28]  M. Zand,et al.  Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. , 1998, Transplantation.

[29]  P. Friend,et al.  Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. , 1995, Transplantation proceedings.

[30]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[31]  Eld,et al.  COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS , PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION , AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT , 2000 .

[32]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.